The immune signaling molecule interleukin 1B (IL-1B) is present at higher levels in mouse models of alcohol use disorder. The IL 1B pathway plays a different role in animal models of AUD, causing inflammation in brain areas that play a critical role in decision-making.
Prazosin, an FDA-approved medication for the treatment of hypertension may help to prevent relapse in people with cardiovascular and behavioral symptoms of alcohol withdrawal, a new study reports.
Apremilast, an FDA-approved drug for the treatment of skin conditions including psoriasis and psoriatic arthritis, triggers increased activity in the nucleus accumbens, a brain area associated with regulating alcohol intake. Apremilast reduced drinking behaviors in mouse models with a genetic risk of alcohol use disorder.
The connection between dopamine and counterfactual information, or notions of relief and regret, is altered in those with alcohol use disorder.
Having a sense of purpose in life decreases alcohol consumption and binge drinking temptation in some social drinkers.
MAP4343, an experimental antidepressant compound reversed alcohol intake in rat models of alcohol use disorder. The findings pave the way for utilizing the compound for the treatment of AUD in humans.
Close and supportive parental relationships can help mitigate the genetic and environmental risk of developing alcohol use disorder for at-risk teens.
Brain levels of FAAH, an enzyme that degrades a neurotransmitter that activates the cannabinoid 1 receptor, may contribute to the maintenance of excessive drinking and susceptibility to alcohol use disorder.
Fathers who binge drink are less involved with their children, a new study reports. Treating paternal heavy alcohol use can improve family dynamics.
Since 2000, marijuana use in young adults has increased by 245%, while alcohol use in adolescents has seen a steady decline.
Those with PTSD are almost twice as likely to develop alcohol use disorder than their peers who have not experienced trauma. Researchers report drugs that block FKBP5, such as benztropine, a drug used to control symptoms of Parkinson's disease, and the experimental compound SAFit2 reduce alcohol preference and drinking in models of PTSD.
Spironolactone, a medication commonly used to lower blood pressure and for treating heart-related problems, shows potential for the treatment of alcohol use disorder.